Do analysts recommend INDP or STTK?

Shattuck Labs has a consensus price target of $12.13, suggesting a potential upside of 63.41%. Given Shattuck Labs' stronger consensus rating and higher possible upside, analysts clearly believe Shattuck Labs is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Shattuck Labs 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.82

Is INDP or STTK more profitable?

Shattuck Labs' return on equity of -43.57% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Indaptus Therapeutics N/A -514.36% -252.43% Shattuck Labs N/A -43.57% -40.90%

Does the media favor INDP or STTK?

In the previous week, Shattuck Labs had 10 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 17 mentions for Shattuck Labs and 7 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.31 beat Shattuck Labs' score of 0.81 indicating that Indaptus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indaptus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Shattuck Labs 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend INDP or ALT?

Altimmune has a consensus target price of $14.33, suggesting a potential upside of 387.53%. Given Altimmune's stronger consensus rating and higher probable upside, analysts clearly believe Altimmune is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Altimmune 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67

Does the media prefer INDP or ALT?

In the previous week, Altimmune had 5 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 12 mentions for Altimmune and 7 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.31 beat Altimmune's score of 0.24 indicating that Indaptus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indaptus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer INDP or ARVN?

Arvinas has a consensus price target of $14.17, suggesting a potential upside of 57.93%. Given Arvinas' stronger consensus rating and higher probable upside, analysts plainly believe Arvinas is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Arvinas 2 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.45

Does the media favor INDP or ARVN?

In the previous week, Indaptus Therapeutics had 1 more articles in the media than Arvinas. MarketBeat recorded 7 mentions for Indaptus Therapeutics and 6 mentions for Arvinas. Indaptus Therapeutics' average media sentiment score of 1.31 beat Arvinas' score of 0.62 indicating that Indaptus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indaptus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arvinas 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer INDP or CTMX?

CytomX Therapeutics has a consensus target price of $11.90, suggesting a potential upside of 254.17%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CytomX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00

Does the media favor INDP or CTMX?

In the previous week, CytomX Therapeutics had 2 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 9 mentions for CytomX Therapeutics and 7 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.31 beat CytomX Therapeutics' score of 0.61 indicating that Indaptus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indaptus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Do analysts prefer MPLT or INDP?

Maplight Therapeutics currently has a consensus target price of $29.67, indicating a potential upside of 152.48%. Given Maplight Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Maplight Therapeutics is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maplight Therapeutics 1 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 4 Strong Buy rating(s) 2.94 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, MPLT or INDP?

Maplight Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maplight Therapeutics N/A N/A -$161.15M -$40.99 N/A Indaptus Therapeutics N/A N/A -$20.85M -$15.40 N/A

Is MPLT or INDP more profitable?

Maplight Therapeutics' return on equity of -118.06% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Maplight Therapeutics N/A -118.06% -59.67% Indaptus Therapeutics N/A -514.36% -252.43%

Does the media favor MPLT or INDP?

In the previous week, Maplight Therapeutics had 1 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 8 mentions for Maplight Therapeutics and 7 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.31 beat Maplight Therapeutics' score of 0.80 indicating that Indaptus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indaptus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Indaptus Therapeutics (INDP) Competitors

$1.07 +0.01 (+0.94%)

Closing price 04:00 PM Eastern

Extended Trading

$1.08 +0.01 (+0.93%)

As of 07:34 PM Eastern

Compare

INDP vs. STTK, ALT, ARVN, CTMX, and MPLT

Should you buy Indaptus Therapeutics stock or one of its competitors? Indaptus Therapeutics's main competitors and comparable companies include Shattuck Labs (STTK), Altimmune (ALT), Arvinas (ARVN), CytomX Therapeutics (CTMX), and Maplight Therapeutics (MPLT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Indaptus Therapeutics compare to Shattuck Labs?

Indaptus Therapeutics (NASDAQ:INDP) and Shattuck Labs (NASDAQ:STTK) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

In the previous week, Shattuck Labs had 10 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 17 mentions for Shattuck Labs and 7 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.31 beat Shattuck Labs' score of 0.81 indicating that Indaptus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indaptus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Shattuck Labs	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Indaptus Therapeutics has higher earnings, but lower revenue than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A
Shattuck Labs	$1M	568.97	-$48.81M	-$0.63	N/A

7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 9.9% of Indaptus Therapeutics shares are owned by company insiders. Comparatively, 8.8% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Shattuck Labs has a consensus price target of $12.13, suggesting a potential upside of 63.41%. Given Shattuck Labs' stronger consensus rating and higher possible upside, analysts clearly believe Shattuck Labs is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Shattuck Labs' return on equity of -43.57% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-514.36%	-252.43%
Shattuck Labs	N/A	-43.57%	-40.90%

Indaptus Therapeutics has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market.

Summary

Shattuck Labs beats Indaptus Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Altimmune?

Indaptus Therapeutics (NASDAQ:INDP) and Altimmune (NASDAQ:ALT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

Indaptus Therapeutics has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -31.41% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-514.36%	-252.43%
Altimmune	-214,860.98%	-31.41%	-26.96%

Indaptus Therapeutics has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

In the previous week, Altimmune had 5 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 12 mentions for Altimmune and 7 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.31 beat Altimmune's score of 0.24 indicating that Indaptus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indaptus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Indaptus Therapeutics has higher earnings, but lower revenue than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A
Altimmune	$40K	14,293.55	-$88.09M	-$0.93	N/A

7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 9.9% of Indaptus Therapeutics shares are owned by insiders. Comparatively, 1.6% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Altimmune has a consensus target price of $14.33, suggesting a potential upside of 387.53%. Given Altimmune's stronger consensus rating and higher probable upside, analysts clearly believe Altimmune is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Altimmune	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Altimmune beats Indaptus Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Arvinas?

Indaptus Therapeutics (NASDAQ:INDP) and Arvinas (NASDAQ:ARVN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Arvinas has a net margin of 2.94% compared to Indaptus Therapeutics' net margin of 0.00%. Arvinas' return on equity of 1.91% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-514.36%	-252.43%
Arvinas	2.94%	1.91%	1.29%

Indaptus Therapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Arvinas has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market.

Arvinas has a consensus price target of $14.17, suggesting a potential upside of 57.93%. Given Arvinas' stronger consensus rating and higher probable upside, analysts plainly believe Arvinas is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Arvinas	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45

In the previous week, Indaptus Therapeutics had 1 more articles in the media than Arvinas. MarketBeat recorded 7 mentions for Indaptus Therapeutics and 6 mentions for Arvinas. Indaptus Therapeutics' average media sentiment score of 1.31 beat Arvinas' score of 0.62 indicating that Indaptus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indaptus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arvinas	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 9.9% of Indaptus Therapeutics shares are owned by insiders. Comparatively, 7.3% of Arvinas shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Indaptus Therapeutics has higher earnings, but lower revenue than Arvinas. Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A
Arvinas	$262.60M	2.20	-$80.80M	$0.10	89.70

Summary

Arvinas beats Indaptus Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Indaptus Therapeutics compare to CytomX Therapeutics?

Indaptus Therapeutics (NASDAQ:INDP) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

In the previous week, CytomX Therapeutics had 2 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 9 mentions for CytomX Therapeutics and 7 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.31 beat CytomX Therapeutics' score of 0.61 indicating that Indaptus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indaptus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Indaptus Therapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market.

7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 9.9% of Indaptus Therapeutics shares are held by company insiders. Comparatively, 3.8% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

CytomX Therapeutics has higher revenue and earnings than Indaptus Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A
CytomX Therapeutics	$76.20M	9.61	-$17.37M	-$0.50	N/A

CytomX Therapeutics has a consensus target price of $11.90, suggesting a potential upside of 254.17%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

Indaptus Therapeutics has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -435.21%. CytomX Therapeutics' return on equity of -38.46% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-514.36%	-252.43%
CytomX Therapeutics	-435.21%	-38.46%	-30.33%

Summary

CytomX Therapeutics beats Indaptus Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

Maplight Therapeutics' return on equity of -118.06% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	-118.06%	-59.67%
Indaptus Therapeutics	N/A	-514.36%	-252.43%

7.1% of Indaptus Therapeutics shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by insiders. Comparatively, 9.9% of Indaptus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Maplight Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A

In the previous week, Maplight Therapeutics had 1 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 8 mentions for Maplight Therapeutics and 7 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.31 beat Maplight Therapeutics' score of 0.80 indicating that Indaptus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indaptus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Maplight Therapeutics currently has a consensus target price of $29.67, indicating a potential upside of 152.48%. Given Maplight Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Maplight Therapeutics is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.94
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Maplight Therapeutics beats Indaptus Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Indaptus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INDP vs. The Competition

Export

Metric	Indaptus Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$120.04M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-0.17	10.67	269.06	25.28
Price / Sales	N/A	1,294.08	602.43	91.76
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	0.76	16.78	12.91	6.24
Net Income	-$20.85M	-$13.32M	$3.45B	$347.60M
7 Day Performance	-9.32%	1.74%	1.12%	1.07%
1 Month Performance	-59.32%	1.60%	1.79%	1.03%
1 Year Performance	-86.30%	56.43%	67.69%	20.77%

Indaptus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INDP Indaptus Therapeutics	1.3073 of 5 stars	$1.07 +0.9%	N/A	-87.4%	$120.04M	N/A	N/A	6	News Coverage Positive News Earnings Report Upcoming Earnings Short Interest Decrease Gap Up
STTK Shattuck Labs	4.0017 of 5 stars	$7.37 -6.9%	$12.63 +71.3%	+802.9%	$607.31M	$1M	N/A	100	News Coverage Earnings Report Analyst Forecast Analyst Revision
ALT Altimmune	2.1055 of 5 stars	$3.03 -1.3%	$15.71 +418.6%	-23.0%	$597.04M	$40K	N/A	50	News Coverage Earnings Report
ARVN Arvinas	2.85 of 5 stars	$8.40 -6.7%	$15.17 +80.6%	+27.1%	$580.69M	$316.70M	84.01	420	High Trading Volume
CTMX CytomX Therapeutics	3.1786 of 5 stars	$3.35 +0.9%	$12.10 +261.2%	+89.3%	$565.02M	$76.20M	N/A	170	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INDP) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Indaptus Therapeutics (INDP) Competitors

INDP vs. STTK, ALT, ARVN, CTMX, and MPLT

How does Indaptus Therapeutics compare to Shattuck Labs?

Summary

How does Indaptus Therapeutics compare to Altimmune?

Summary

How does Indaptus Therapeutics compare to Arvinas?

Summary

How does Indaptus Therapeutics compare to CytomX Therapeutics?

Summary

How does Indaptus Therapeutics compare to Maplight Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDP vs. The Competition

Indaptus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Indaptus Therapeutics (INDP) Competitors

INDP vs. STTK, ALT, ARVN, CTMX, and MPLT

How does Indaptus Therapeutics compare to Shattuck Labs?

Does the media favor INDP or STTK?

Which has better valuation & earnings, INDP or STTK?

Do insiders and institutionals have more ownership in INDP or STTK?

Do analysts recommend INDP or STTK?

Is INDP or STTK more profitable?

Which has more volatility and risk, INDP or STTK?

Summary

How does Indaptus Therapeutics compare to Altimmune?

Is INDP or ALT more profitable?

Which has more risk and volatility, INDP or ALT?

Does the media prefer INDP or ALT?

Which has higher earnings and valuation, INDP or ALT?

Do insiders and institutionals have more ownership in INDP or ALT?

Do analysts recommend INDP or ALT?

Summary

How does Indaptus Therapeutics compare to Arvinas?

Is INDP or ARVN more profitable?

Which has more volatility and risk, INDP or ARVN?

Do analysts prefer INDP or ARVN?

Does the media favor INDP or ARVN?

Do institutionals & insiders have more ownership in INDP or ARVN?

Which has preferable valuation and earnings, INDP or ARVN?

Summary

How does Indaptus Therapeutics compare to CytomX Therapeutics?

Does the media favor INDP or CTMX?

Which has more volatility & risk, INDP or CTMX?

Do institutionals and insiders have more ownership in INDP or CTMX?

Which has stronger earnings & valuation, INDP or CTMX?

Do analysts prefer INDP or CTMX?

Is INDP or CTMX more profitable?

Summary

How does Indaptus Therapeutics compare to Maplight Therapeutics?

Is MPLT or INDP more profitable?

Do institutionals and insiders hold more shares of MPLT or INDP?

Which has preferable valuation & earnings, MPLT or INDP?

Does the media favor MPLT or INDP?

Do analysts prefer MPLT or INDP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDP vs. The Competition

Indaptus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools